Telix Pharmaceuticals Limited ADR (TLX)

$16.96 +0.16 (0.98%)
Market Cap 5.74B
Revenue (ttm) 516.68M
Net Income (ttm) 32.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 32.30
Profit Margin 6.37%
Debt to Equity Ratio 1.00
Volume 8,100
Avg Vol 22,390
Day's Range N/A - N/A
Shares Out 338.25M
Stochastic %K 36%
Beta N/A
Analysts Strong Sell
Price Target $23.50

Company Profile

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate ca...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9093 3855
Address:
55 Flemington Road, Suite 401, North Melbourne, Australia
Latest News on TLX
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

Jun 19, 2025, 8:18 PM EDT - 8 hours ago

Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

Telix Investor Day in New York City on June 11, 2025: Presenting KOLs

Jun 3, 2025, 6:57 AM EDT - 16 days ago

Telix Investor Day in New York City on June 11, 2025: Presenting KOLs

Telix Pharmeceuticals: Imaging Biomarkers Paving The Way For Theranostics

May 13, 2025, 5:36 AM EDT - 5 weeks ago

Telix Pharmeceuticals: Imaging Biomarkers Paving The Way For Theranostics

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

May 7, 2025, 4:13 PM EDT - 6 weeks ago

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

Apr 28, 2025, 6:30 PM EDT - 7 weeks ago

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

Telix Reports US$186M Q1 Revenue, Up 62% YOY

Apr 22, 2025, 4:17 AM EDT - 2 months ago

Telix Reports US$186M Q1 Revenue, Up 62% YOY

Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients

Apr 16, 2025, 10:57 AM EDT - 2 months ago

Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

Apr 15, 2025, 6:37 PM EDT - 2 months ago

IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate

Telix Announces Cardinal Health for Gozellix Commercial Distribution

Apr 8, 2025, 6:30 AM EDT - 2 months ago

Telix Announces Cardinal Health for Gozellix Commercial Distribution

Telix Appoints Paul Schaffer as Chief Technology Officer

Apr 7, 2025, 6:30 AM EDT - 2 months ago

Telix Appoints Paul Schaffer as Chief Technology Officer

Telix Pharmaceuticals: Building A Radiopharma Powerhouse

Apr 5, 2025, 1:03 AM EDT - 2 months ago

Telix Pharmaceuticals: Building A Radiopharma Powerhouse

Anne Whitaker Appointed as Non-Executive Director

Apr 3, 2025, 6:13 PM EDT - 2 months ago

Anne Whitaker Appointed as Non-Executive Director

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

Apr 1, 2025, 3:30 PM EDT - 2 months ago

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix®

Apr 1, 2025, 8:49 AM EDT - 2 months ago

ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix®

Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent

Mar 21, 2025, 11:06 AM EDT - 3 months ago

Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

Mar 21, 2025, 6:30 AM EDT - 3 months ago

FDA Approves New Prostate Cancer Imaging Agent Gozellix®

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

Mar 17, 2025, 5:53 PM EDT - 3 months ago

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

Telix Adds Lead-212 Isotope Production Capability

Mar 12, 2025, 6:41 PM EDT - 3 months ago

Telix Adds Lead-212 Isotope Production Capability

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

Mar 3, 2025, 4:48 PM EST - 3 months ago

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review

Feb 25, 2025, 6:51 PM EST - 4 months ago

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review

Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami

Feb 25, 2025, 7:30 AM EST - 4 months ago

Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami

Australia's Telix Pharmaceuticals scales record peak on upbeat revenue forecast

Feb 20, 2025, 9:37 PM EST - 4 months ago

Australia's Telix Pharmaceuticals scales record peak on upbeat revenue forecast

Telix Pharmaceuticals Limited (TLPPF) FY 2024 Results Earnings Call Transcript

Feb 20, 2025, 9:29 PM EST - 4 months ago

Telix Pharmaceuticals Limited (TLPPF) FY 2024 Results Earnings Call Transcript

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

Feb 20, 2025, 7:10 AM EST - 4 months ago

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

Feb 13, 2025, 7:00 AM EST - 4 months ago

Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

Illuccix® Approved in the United Kingdom

Feb 12, 2025, 4:38 PM EST - 4 months ago

Illuccix® Approved in the United Kingdom

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Jan 30, 2025, 4:57 PM EST - 5 months ago

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Telix Completes Acquisition of RLS (USA) Inc.

Jan 27, 2025, 4:43 PM EST - 5 months ago

Telix Completes Acquisition of RLS (USA) Inc.

ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery

Jan 22, 2025, 12:55 PM EST - 5 months ago

ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery

Illuccix® Receives European Approval

Jan 16, 2025, 5:06 PM EST - 5 months ago

Illuccix® Receives European Approval

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 4:35 PM EST - 5 months ago

Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Jan 13, 2025, 2:08 AM EST - 5 months ago

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Jan 12, 2025, 5:04 PM EST - 5 months ago

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

Dec 30, 2024, 3:45 PM EST - 6 months ago

NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Dec 29, 2024, 4:53 PM EST - 6 months ago

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

Nov 18, 2024, 6:20 PM EST - 7 months ago

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

Telix ADSs Commence Trading on Nasdaq

Nov 13, 2024, 4:28 PM EST - 7 months ago

Telix ADSs Commence Trading on Nasdaq